|

Pegfilgrastim Clinical Trials

15 actively recruiting trials across 10 locations

▲ +1 trial since August 2026

Also known as: Cegfila, Dulastin, Dyrupeg, Filgrastim SD-01, Fulphila +50 more

Pipeline

Phase 1: 1Phase 2: 8Phase 3: 2Phase 1/2: 3Phase 2/3: 1

Top Sponsors

  • M.D. Anderson Cancer Center3
  • University of Washington2
  • St. Jude Children's Research Hospital2
  • University of California, Irvine1
  • The Affiliated People's Hospital of Ningbo University1

Indications

  • Cancer15
  • Follicular Helper T-Cell Lymphoma, Not Otherwise Specified1
  • Follicular Helper T-Cell Lymphoma, Follicular-Type1
  • Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type1
  • Follicular Helper T-Cell Lymphoma1

Houston, Texas3 trials

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

M D Anderson Cancer Center

Phase 2
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M D Anderson Cancer Center

Phase 2
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2

Other2 trials

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Phase 3
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Phase 3

Seattle, Washington2 trials

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Birmingham, Alabama1 trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Children's Hospital of Alabama

Phase 2

Kingman, Arizona1 trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Kingman Regional Medical Center

Phase 2/3

Davis, California1 trial

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

University of California Davis

Phase 2

Duarte, California1 trial

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

City of Hope Medical Center

Phase 1

Orange, California1 trial

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Chao Family Comprehensive Cancer Center University of California, Irvine

Phase 1/2

Palo Alto, California1 trial

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Lucille Packard Children's Hospital Stanford

Phase 2

Boston, Massachusetts1 trial

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Boston Children's Hospital

Phase 1/2

Memphis, Tennessee1 trial

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.